Drug counterfeiting may cost the worldwide pharmaceutical industry more than US$30 billion annually. Radio frequency identification — RFID — seen as one way to lower that cost, has its own defining characteristics. Issues of drug counterfeiting and patient safety differentiate it from RFID in retail markets.
To minimize this wastage, and to raise the level of safety for patients, some companies are embracing RFID tagging of drug shipments at the item level. At least three major manufacturers — Pfizer, GlaxoSmithKline and Purdue Pharma — have announced plans to tag their products.
Will companies use UHF or HF technology for item level tracking?
How is pharmaceutical tracking different from supply chain management?
How will this market grow over the next four years?
To learn more about the RFID life sciences market and how it may affect your business model now and in the future, please visit: The RFID Life Sciences Market.
